Essa Pharma's product candidate pipeline for prostate cancer treatment

ESSA’s primary research efforts are focused on developing small molecule therapies to treat patients with prostate cancer. Our lead candidate, EPI-7386, is a highly-selective, oral, small molecule that inhibits the androgen receptor (AR) through a novel mechanism of action (N-terminal domain inhibition). We believe that our approach is highly differentiated and has the potential to bypass current androgen receptor-based resistance mechanisms that develop in patients with castration resistant prostate cancer (CRPC) and metastatic castration-resistant prostate cancer (mCRPC).

Trials

Clinical Monotherapy Trial

ESSA is evaluating EPI-7386 as a monotherapy for the treatment of adult male patients with mCRPC resistant to standard-of-care treatments.

Collaboration Trials

We are planning to evaluate EPI-7386 in clinical studies in combination with currently approved second-generation antiandrogen therapies as an earlier line of treatment for patients with mCRPC. Based upon preclinical studies, ESSA believes that by inhibiting both the N-terminal domain and the ligand-binding domain, greater suppression of the androgen receptor may result in greater suppression of androgen activity and potentially delay or prevent drug resistance.

EPI-7386

Program Prog	Indication Ind	Research Res
EPI-7386 monotherapy
EPI-7386 monotherapy	mCRPC - Resistant to standard of care treatments*	mCRPC - Resistant to standard of care treatments*
EPI-7386 monotherapy	Non-PC AR-Driven Cancers	Non-PC AR-Driven Cancers
EPI-7386 + enzalutamide
EPI-7386 + enzalutamide	mCRPC	mCRPC
EPI-7386 + abiraterone acetate + prednisone
EPI-7386 + abiraterone acetate + prednisone	mCRPC	mCRPC
EPI-7386 + apalutamide
EPI-7386 + apalutamide	mCRPC	mCRPC
EPI-7386 + darolutamide
EPI-7386 + darolutamide	mCRPC	mCRPC

* Phase 1 clinical update expected during the first half of 2022.
** Bayer and Janssen will be conducting their respective combination trials. ESSA is conducting the combination trial with Astellas.

Discovery

Program Prog	Indication Ind	Research Res
3rd-Generation AR N-Terminal Domain Inhibitor
3rd-Generation AR N-Terminal Domain Inhibitor	Prostate Cancer	Prostate Cancer
AR N-Terminal Domain Tau-1 Site Inhibitor
AR N-Terminal Domain Tau-1 Site Inhibitor	Prostate Cancer	Prostate Cancer
AR N-Terminal Domain Degrader
AR N-Terminal Domain Degrader	Prostate Cancer	Prostate Cancer

Product Candidates

Pipeline